Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 12/2007

01-12-2007 | Case Report

Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients

Authors: Senol Kobak, Fahrettin Oksel, Yasemin Kabasakal, Eker Doganavsargil

Published in: Clinical Rheumatology | Issue 12/2007

Login to get access

Abstract

Secondary (AA) amyloidosis is one of the most significant complications of ankylosing spondylitis (AS) that frequently leads to proteinuria and renal dysfunction. Anti-tumor necrosis factor alpha (anti-TNF) agents are promising in inducing clinical remission by suppressing systemic inflammation in AA amyloidosis. We report three cases with AS-related AA amyloidosis that responded well to etanercept therapy. Despite treatment with disease modifying anti-rheumatic drugs, all three patients had active AS, marked proteinuria, impaired renal function, and low serum albumin level. During 1-year treatment with etanercept, all patients experienced gradual improvement in all of these parameters.
Literature
1.
2.
Buxbaum J (1998) The amyloidoses. In: Klippel JH, Dieppe PA (eds) Rheumatology, 2nd edn. Mosby, St. Louis, pp 5.24.7–10
3.
Mladenovic J, Geisic L, Kerimovic D, Aramasic M, Merovic Z (1975) Incidence of amyloidosis in rheumatoid arthritis and ankylosing spondylitis. Scand J Rheumatol 4(Suppl 8):39
4.
Hazenberg BP, van Rijswijk MH (1994) Clinical and therapeutic aspects of AA amyloidosis. Baillieres Clin Rheumatol 8:661–690CrossRefPubMed
5.
6.
Urieli-Shoval S, Linke RP, Matzner Y (2000) Expression and function of serum amyloid A, a major acute phase protein, in normal and disease states. Curr Opin Hematol 7:64–69CrossRefPubMed
7.
Yan SD, Zhu H, Zhu A et al (2000) Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 6:643–651CrossRefPubMed
8.
Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H (2000) The receptor for advanced by the glycation products themselves and tumor necrosis factor-α through nuclear factor-κb and by 17β-estradiol through Sp-1in human vascular endothelial cells. J Biol Chem 33:25781–25790CrossRef
9.
Shibasaki T, Matsumoto H, Watabe K et al (1997) A case of renal amyloidosis associated with hepatic adenoma: the pathogenetic role of tumour necrosis factor-alpha. Nephron 75:350–353CrossRefPubMed
10.
Cunnane G, Whitehead AS (1999) Amyloid precursors and amyloidosis in rheumatoid arthritis. Baillieres Best Pract Res Clin Rheumatol 13:615–628CrossRefPubMed
11.
Fernandez-Nebro A, Tomero E, Ortiz-Santamaria V, Castro MC, Olive A, de Haro M, Garcia-Vicuna R, Gonzalez-Mari MV, Laffon A, Garcia-Vicuna R (2005) Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am J Med 118:552–556CrossRefPubMed
12.
Gottenberg JE, Merle-Vincent F, Bentaberry F et al (2003) Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum 48:2019–2024CrossRefPubMed
13.
Drewe E, McDermott EM, Powell RJ (2000) Treatment of the nephrotic syndrome with etanercept in patients with the tumor necrosis factor receptor-associated periodic syndrome (letter). N Engl J Med 343:1044–1045CrossRefPubMed
14.
Elkayam O, Hawkins PN, Lachmann H, Yaron M, Caspi D (2002) Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum 46:2571–2573CrossRefPubMed
Metadata
Title
Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients
Authors
Senol Kobak
Fahrettin Oksel
Yasemin Kabasakal
Eker Doganavsargil
Publication date
01-12-2007
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 12/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-007-0679-x

Other articles of this Issue 12/2007

Clinical Rheumatology 12/2007 Go to the issue

Erratum

Erratum to: Accessory navicular bone: when ankle pain does not originate from the ankle

Case Report

Osseous mastocytosis of the knee

Original Article

Prognosis of clinical renal disease and incidence of new renal findings in patients with rheumatoid arthritis: follow-up of a population-based study

Original Article

Clinical and serological correlates of antinucleosome antibodies in South Africans with systemic lupus erythematosus

Original Article

Accurate diagnosis of acute abdomen in FMF and acute appendicitis patients: how can we use procalcitonin?

Case Report

Pericarditis: a rare complication of methotrexate therapy
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits